[go: up one dir, main page]

MX2010010791A - Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito. - Google Patents

Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito.

Info

Publication number
MX2010010791A
MX2010010791A MX2010010791A MX2010010791A MX2010010791A MX 2010010791 A MX2010010791 A MX 2010010791A MX 2010010791 A MX2010010791 A MX 2010010791A MX 2010010791 A MX2010010791 A MX 2010010791A MX 2010010791 A MX2010010791 A MX 2010010791A
Authority
MX
Mexico
Prior art keywords
endothelial
cyclopentadione
substituted
attenuated
inflammation
Prior art date
Application number
MX2010010791A
Other languages
English (en)
Inventor
Konda Veera
Desai Anu
S Bland Jeffrey
L Tripp Matthew
Darland Gary
Lamb Joseph
A Emma Dennis
Original Assignee
Metaproteomics Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics Llc Star filed Critical Metaproteomics Llc Star
Publication of MX2010010791A publication Critical patent/MX2010010791A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/707Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a three- to five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para reducir el riesgo cardiovascular utilizando compuestos de 1,3-ciclopentadiona sustituida como se describen.
MX2010010791A 2008-04-02 2009-04-02 Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito. MX2010010791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4163108P 2008-04-02 2008-04-02
PCT/US2009/039272 WO2009124176A1 (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions

Publications (1)

Publication Number Publication Date
MX2010010791A true MX2010010791A (es) 2011-03-04

Family

ID=41135936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010791A MX2010010791A (es) 2008-04-02 2009-04-02 Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito.

Country Status (10)

Country Link
US (1) US20100222262A1 (es)
EP (1) EP2268600A4 (es)
JP (1) JP2011516492A (es)
KR (1) KR20110010603A (es)
CN (1) CN102066303A (es)
AU (1) AU2009231723B2 (es)
CA (1) CA2720546A1 (es)
MX (1) MX2010010791A (es)
NZ (1) NZ588927A (es)
WO (1) WO2009124176A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US20110275721A1 (en) * 2008-12-10 2011-11-10 Metaproteomics, Llc Method for the purification of substituted cyclopent-2-en-1-one congeners and substituted 1,3-cyclopentadione congeners from a complex mixture using countercurrent separation
AU2013290297B2 (en) * 2012-07-09 2017-11-02 Kindex Pharmaceuticals, Inc. Tetrahydro-isohumulone derivatives, methods of making and using
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933919A (en) * 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
US3451821A (en) * 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
GB1145240A (en) * 1965-03-01 1969-03-12 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3536495A (en) * 1968-03-13 1970-10-27 Miller Brewing Ammonia complexes of hop alpha acids and modified alpha acids
US3975442A (en) * 1970-12-09 1976-08-17 Hoffmann-La Roche Inc. 2-Alkyl-2-(3-oxoalkyl)-1,3-cyclopentadiones
US3720517A (en) * 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
US3932603A (en) * 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
US3965188A (en) * 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
JPS4926272A (es) * 1972-07-05 1974-03-08
CH617326A5 (es) * 1975-12-04 1980-05-30 Siegfried Ag
US4148873A (en) * 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4170638A (en) * 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4123561A (en) * 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) * 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
US4389421A (en) * 1981-10-30 1983-06-21 Busch Industrial Products Corporation Method for controlling light stability in malt beverages and product thereof
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4644084A (en) * 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
US4590296A (en) * 1984-01-25 1986-05-20 Miller Brewing Company Process for separation of beta-acids from extract containing alpha-acids and beta-acids
DE3513169A1 (de) * 1985-04-12 1986-10-16 Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach Verfahren zur herstellung von isohumulonen
US4767640A (en) * 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) * 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
US5041300A (en) * 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
DE3712986A1 (de) * 1987-04-16 1988-10-27 Marbert Gmbh Medizinische zubereitungen auf der grundlage von biertreberextrakt, verfahren zu deren herstellung sowie verwendung von biertreberextrakt zur herstellung von kosmetischen zubereitungen und ein spezieller biertreberextrakt
US4857554A (en) * 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5082975A (en) * 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5013571A (en) * 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
EP0474892B1 (de) * 1990-09-10 1996-04-10 Fromm, Mayer-Bass Limited Verfahren zur Isomerisierung von Humulon in einem Kohlendioxid-Hopfenextrakt und ein Verfahren zur Gewinnung von Isohumulon daraus
TW199905B (en) * 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
JP3065353B2 (ja) * 1992-07-29 2000-07-17 ドライムド エイエス 受精卵を含む組成物
US5286506A (en) * 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5296637A (en) * 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
JP2677762B2 (ja) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 油冷式圧縮機
DE69507185T2 (de) * 1994-04-12 1999-09-09 Hoechst Marion Roussel Arzneimittel zur Behandlung von Osteoporose
IN184685B (es) * 1996-02-14 2000-09-23 Nat Inst Immunology
US5827895A (en) * 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) * 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5968539A (en) * 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
US6224871B1 (en) * 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2147538B1 (es) * 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6462029B1 (en) * 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
AU7596100A (en) * 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6200594B1 (en) * 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) * 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
WO2001072265A1 (fr) * 2000-03-31 2001-10-04 The Nisshin Oil Mills, Ltd. Preparation externe pour la peau et agents d'embellissement
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6908630B2 (en) * 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (fr) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7078062B2 (en) * 2001-01-17 2006-07-18 S.S. Steiner, Inc. Hop-based udder and teat dips and washes
US20030035851A1 (en) * 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US20030003212A1 (en) * 2001-06-13 2003-01-02 Givaudan Sa Taste modifiers
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
PT1446136E (pt) * 2001-10-26 2010-12-29 Metaproteomics Llc Composições curcuminóides exibindo inibição sinérgica da expressão e/ou actividade de ciclooxigenase-2
US7108868B2 (en) * 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7409939B2 (en) * 2002-09-16 2008-08-12 Perkins Engines Company Limited Cylinder head having an integrally cast rocker shaft pedestal
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
DE602004019967D1 (de) * 2003-12-16 2009-04-23 Basell Polyolefine Gmbh Monocyclopentadienylkomplexe
EP1718152A4 (en) * 2004-01-28 2009-09-16 Merck & Co Inc AMINOCYCLOPENTYLPYRIDOPYRAZINONE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US20070065456A1 (en) * 2005-09-20 2007-03-22 Woods Cindy J Nutritional supplements
NZ568860A (en) * 2005-12-09 2012-09-28 Metaproteomics Llc Protein kinase modulation by hops and acacia products
US8062898B2 (en) * 2006-10-20 2011-11-22 The Board Of Trustees Of The University Of Illinois Selection and rational development of solvent systems in counter-current chromatograph

Also Published As

Publication number Publication date
EP2268600A1 (en) 2011-01-05
NZ588927A (en) 2013-02-22
US20100222262A1 (en) 2010-09-02
AU2009231723B2 (en) 2014-04-17
EP2268600A4 (en) 2012-03-21
JP2011516492A (ja) 2011-05-26
WO2009124176A1 (en) 2009-10-08
WO2009124176A8 (en) 2010-11-18
CA2720546A1 (en) 2009-10-08
KR20110010603A (ko) 2011-02-01
CN102066303A (zh) 2011-05-18
AU2009231723A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
IL232095A0 (en) Preparations based on type iii fibronectin ether scaffold, methods and uses
MX2010000593A (es) Aumentador del vigor de una planta.
IN2012DN02046A (es)
MY155242A (en) Antireflective coating compositions
SG169988A1 (en) Rnai inhibition of alpha-enac expression
AP2012006278A0 (en) Compositions for treating centrally mediated nausea and vomiting.
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
MX2009010081A (es) Metodos y composiciones relacionadas con los ribointerruptores (riboswitches) que controlan el corte y empalme (splicing) alternativo.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
MY149433A (en) Nutritional compositions containing punicalagins
MX2010010791A (es) Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito.
SI2113254T1 (sl) Sestave za zdravljenje vnetnih avtoimunskih stanj
MX2009009822A (es) Composiciones y metodos para reducir niveles de h2s en bebidas fermentadas.
ZA201007330B (en) Novel pyriproxyfen compositions
PL2262828T3 (pl) Kompozycje, sposoby i zestawy
UA99332C2 (en) Herbicidal combinations having diflufenican and pinoxaden and use thereof
WO2009088939A3 (en) Compositions and methods for treating neurodegenerative diseases
ZA201101520B (en) Phenanthrenone compounds,compositions and methods
WO2011006097A3 (en) Methods For Treating Toxicity
AU2015201137B2 (en) Compositions and method for tissue preservation
HK1147088A (en) Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
WO2009126778A3 (en) Compositions and methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal